dissemination

[키워드] adaptive Administered administration aggregate authorization bamlanivimab Bayesian blinded Blinding calculated captures Casirivimab collected Comorbidities comparator composite endpoint Course COVID-19 criteria dependent on determine determined by dissemination distribution Dosing drug Effectiveness effort element eligibility criteria Emergency emergency department Emergency Departments etesevimab EUA evaluate evaluated FDA Final Follow-up food futility Government high risk hospital Hospitalization Hospitalized Identifier Imdevimab Impact include increase in inferiority infusion Intervention investigator investigators mAbs manuscript medical record Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal antibodies monoclonal antibody monotherapy number obese objective Open-label outcome outcome assessor outcome assessors oxygen pandemic participant Patient physician Platform trial Pragmatic pragmatic trial Primary outcome protocol provide random random allocation randomised randomised controlled trial randomization reached receive recorded recruitment routine clinical care Sample Sample size SARS-CoV-2 variant SARS-CoV-2 variants severe COVID-19 statistical statistical inference status Study protocol submission supplementary material supply sustained Symptoms System the patient the United State therapeutic Treatment treatment of COVID-19 Trial Trial registration United States US Food and Drug Administration Version Volume website
[DOI] 10.1186/s13063-021-05316-3 PMC 바로가기 [Article Type] Letter